AstraZeneca Annual Report and Form 20-F Information 2011

Non-Executive Directors’ fees£Chairman’s fee 500,000Basic fee 75,000Senior independent Non-Executive Director 30,000Membership of the Audit Committee 20,000Membership of the Remuneration Committee 15,000Chairman of the Audit Committee or the Remuneration Committee 1 20,000Membership of the Science Committee 10,000Chairman of the Science Committee 1 7,0001This fee is in addition to the fee for membership of the relevant Committee.Directors’ emoluments in 2011The aggregate remuneration, excluding pension contributions and the value of shares under option and shares subject to Share Awards,paid to or accrued for all Directors for services in all capacities during the year ended 31 December 2011 was £6,535,000 ($10,458,000).The remuneration of individual Directors is set out below in pounds sterling and US dollars. All salaries, fees, bonuses and other benefits forDirectors are established in pounds sterling.Directors’ remuneration – pounds sterlingNameSalaryand fees£000Bonuscash£000BonusShares 1£000Taxablebenefits£000Otherpaymentsandallowances£000Total2011£000Total2010£000Total2009£000Louis Schweitzer 500 – – – – 500 456 325David Brennan 997 2 884 442 24 1,023 3 3,370 3,044 3,186Simon Lowth 636 513 257 6 373 4 1,785 1,642 1,426Bruce Burlington 98 – – – – 98 33 –Jean-Philippe Courtois 95 – – – – 95 80 75Michele Hooper 145 – – – – 145 120 100Rudy Markham 110 – – – – 110 90 75Nancy Rothwell 107 – – – – 107 96 92Shriti Vadera 95 – – – – 95 – –John Varley 110 – – – – 110 99 95Marcus Wallenberg 85 – – – – 85 71 60Former DirectorsJane Henney 35 5 – – – – 35 90 85Others – – – – – – 59 659Total 3,013 1,397 699 30 1,396 6,535 5,880 6,178Directors’ remuneration – US dollarsNameSalaryand fees$000Bonuscash$000BonusShares 1$000Taxablebenefits$000Otherpaymentsandallowances$000Total2011$000Total2010$000Total2009$000Louis Schweitzer 800 – – – – 800 705 504David Brennan 1,596 2 1,415 707 38 1,637 3 5,393 4,705 4,937Simon Lowth 1,018 821 411 10 597 4 2,857 2,537 2,209Bruce Burlington 157 – – – – 157 51 –Jean-Philippe Courtois 152 – – – – 152 124 116Michele Hooper 232 – – – – 232 185 155Rudy Markham 176 – – – – 176 139 116Nancy Rothwell 171 – – – – 171 148 143Shriti Vadera 152 – – – – 152 – –John Varley 176 – – – – 176 153 147Marcus Wallenberg 136 – – – – 136 110 93Former DirectorsJane Henney 56 5 – – – – 56 139 132Others – – – – – – 92 1,021Total 4,822 2,236 1,118 48 2,234 10,458 9,088 9,573Corporate Governance1These figures represent that portion of the 2011 bonuses required to be deferred into Ordinary Shares to be held for a three-year period under the Deferred Bonus Plan.2This figure includes a sum of £447,000 ($719,000) in respect of member contributions to the 401(k) plan and to the AstraZeneca Executive Deferred Compensation Plan which was paid into the plans bymeans of a salary sacrifice (see the Defined contribution arrangements section on page 118 for further details).3Relates to relocation allowances, a car allowance and cash of £880,000 ($1,408,000) on the vesting of a PSP Share Award and £73,000 ($117,000) on the release of Ordinary Shares under the DeferredBonus Plan, in each case paid in respect of dividends accrued.4Relates to remaining cash following selection of benefits within AstraZeneca’s UK flexible benefits programme and cash of £318,000 ($509,000) on the vesting of a PSP Share Award and £6,000($10,000) on the release of shares under the Deferred Bonus Plan, in each case paid in respect of dividends accrued.5Part-year only as ceased to be a Director on 28 April 2011.AstraZeneca Annual Report and Form 20-F Information 2011Directors’ Remuneration Report 123